

Clinical trials of SLV320

TrialResults-center www.trialresultscenter.org

1 acute heart failure

Trial	Treatments	Patients	Trials design and methods
SLV320 vs placebo			
Reno-Defend 1 <i>ongoing</i> [NCT00744341] n=NA follow-up:	2.5, 7.5, 15, and 30 mg/d SLV320 (1 hour intravenous infusions of 1.25, 3.75, 7.5, and 15 mg SLV320, every 12 hours for 3 days [a total of 6 doses] in addition to standard therapy) versus placebo	Subjects Hospitalized With Acute Decompensated Heart Failure and Renal Dysfunction	
S320.2.002 <i>ongoing</i> [NCT00160134] n=NA follow-up:	-	subjects with congestive heart failure requiring diuretic treatment	

More details and results :

- diuretics for acute heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q639>
- new drug under development for acute heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q640>

References

Reno-Defend 1, 0:

ongoing trial NCT00744341

Pang PS, Mehra M, Maggioni AP, Filippatos G, Middlebrooks J, Turlapaty P, Kazei D, Gheorghiade M Rationale, design, and results from RENO-DEFEND 1: a randomized, dose-finding study of the selective A1 adenosine antagonist SLV320 in patients hospitalized with acute heart failure. Am Heart J 2011;161:1012-23.e3 [21641345]

S320.2.002, 0:

ongoing trial NCT00160134